Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IMNN | US
0.01
0.71%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.99
1.02
1.02
0.95
Imunon Inc. a clinical stage biotechnology company engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001 a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma. It also has two platform technologies such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The company was formerly known as Celsion Corporation and changed its name to Imunon Inc. in September 2022. Imunon Inc. was founded in 1982 and is based in Lawrenceville New Jersey.
View LessStrength based on increasing price with high volume
Low Debt to Asset (< 0.2)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
35.3%1 month
47.2%3 months
384.7%6 months
279.6%-
-
3.79
0.37
0.14
0.91
4.00
-
-19.62M
14.29M
14.29M
-
-
-
-
-143.19
1.64
3.01
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.12
Range1M
0.13
Range3M
2.72
Rel. volume
1.30
Price X volume
237.35K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Apollomics Inc. Class A Ordinary Shares | APLM | Biotechnology | 0.1368 | 15.04M | 6.79% | n/a | 21.43% |
| Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 1.47 | 14.99M | -2.63% | n/a | 2.12% |
| Cingulate Inc. Common Stock | CING | Biotechnology | 4.92 | 14.98M | 7.19% | n/a | 10.72% |
| ImmunoPrecise Antibodies Ltd | IPA | Biotechnology | 0.5352 | 14.94M | -0.89% | n/a | 49.00% |
| Cara Therapeutics Inc | CARA | Biotechnology | 0.2656 | 14.57M | 0.19% | n/a | 406.66% |
| Evogene Ltd | EVGN | Biotechnology | 2.58 | 14.44M | 7.50% | n/a | 26.41% |
| Evaxion Biotech A/S | EVAX | Biotechnology | 2.54 | 14.17M | -3.79% | n/a | 837.11% |
| Cyclacel Pharmaceuticals Inc | CYCCP | Biotechnology | 7.3 | 13.88M | 0.00% | n/a | 0.50% |
| Tenax Therapeutics Inc | TENX | Biotechnology | 4.05 | 13.81M | 2.53% | n/a | 3.14% |
| Aytu BioScience Inc | AYTU | Biotechnology | 2.23 | 13.71M | -2.62% | n/a | 54.59% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
| Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.91 | - | Expensive |
| Ent. to Revenue | 4.00 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.79 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 384.71 | - | Riskier |
| Debt to Equity | 0.37 | -1.23 | Expensive |
| Debt to Assets | 0.14 | 0.25 | Cheaper |
| Market Cap | 14.29M | - | Emerging |